Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InotivSTU:BS50 EV-to-EBITDA is 69.15 as of Sep. 16, 2026, which is 425% above its 10-year median of 13.18. The stock has 4 warning signs investors should review. Among 124 Medical Diagnostics & Research companies, Inotiv ranks worse than 91.13% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Inotiv's enterprise value is €409.6 Mil.
Inotiv's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €5.9 Mil. Therefore, Inotiv's EV-to-EBITDA for today is 69.15.
The historical rank and industry rank for Inotiv's EV-to-EBITDA or its related term are showing as below:
STU:BS50'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -72.74 Med: 13.18 Max: 282.07
Current: 69.03
During the past 13 years, the highest EV-to-EBITDA of Inotiv was 282.07. The lowest was -72.74. And the median was 13.18.
STU:BS50's EV-to-EBITDA is ranked worse than 91.13% of 124
companies
in the Medical Diagnostics & Research industry
Industry Median: 16.195
vs STU:BS50: 69.03
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-09-16), Inotiv's stock price is €0.04.
Inotiv's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-2.175. Therefore, Inotiv's PE Ratio (TTM) for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Inotiv's share price for today is €0.04.
Inotiv's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.175.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Inotiv's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:BS50 vs PRPH, NSTM, FUNI: EV-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Inotiv's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inotiv EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Inotiv's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Inotiv's EV-to-EBITDA falls into.
Inotiv's current Enterprise Value is €409.6 Mil.
Inotiv's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €5.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inotiv (STU:BS50) has a EV-to-EBITDA of 69.15 as of Sep. 16, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Inotiv. This is 425% above median its historical median of 13.18. According to the industry distribution chart, Inotiv ranks #113 out of 124 companies in the Medical Diagnostics & Research industry, placing it in the top 91.1%.
Is Inotiv's EV-to-EBITDA too high?
Inotiv's current EV-to-EBITDA of 69.15 is 425% above median its 10-year median of 13.18. The Medical Diagnostics & Research industry median EV-to-EBITDA is 16.20. Inotiv's value of 69.15 is 327% above this industry median. Based on the distribution chart, Inotiv ranks #113 out of 124 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Inotiv's EV-to-EBITDA compare to PRPH and NSTM?
According to the Medical Diagnostics & Research industry distribution chart, Inotiv ranks #113 out of 124 companies for EV-to-EBITDA. This places Inotiv in the lower half of its industry. The industry median EV-to-EBITDA is 16.20. Inotiv's value of 69.15 is 327% above this benchmark. While the company's 10-year median is 13.18 vs. the industry median of 16.20, Inotiv has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 16.20, based on 124 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inotiv's current EV-to-EBITDA of 69.15 is 327% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Inotiv. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inotiv's current EV-to-EBITDA is 69.15, which is 425% above median its own 10-year median of 13.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inotiv stock overvalued right now?
Inotiv (STU:BS50) has a current EV-to-EBITDA of 69.15. The stock's GF Value™ is €6.13, compared to a current price of €0.04 — trading 99.3% below its estimated fair value. The current EV-to-EBITDA is 69.15, which is 425% above median its 10-year median of 13.18 and 327% above the Medical Diagnostics & Research industry median of 16.20. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Inotiv (STU:BS50), the current EV-to-EBITDA is 69.15 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:BS50 has been successfully added to your 
